Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- J. Lipid Res. (5)
- Proc. Natl. Acad. Sci. U.S.A. (2)
- Am. J. Physiol. Gastrointest. Liver Physiol. (2)
- Others (26)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ou MC et al. | Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. | 1994 | Thromb. Res. | pmid:8191415 |
| Eche N et al. | Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). | 1986 | Thromb. Res. | pmid:3726808 |
| Powling MJ and Hardisty RM | Differential effects of 12-O-tetradecanoylphorbol 13-acetate on platelet responses to various agonists in the presence and absence of extracellular Ca2+. | 1986 | Thromb. Res. | pmid:3787566 |
| Slattery CW and Beaumont DO | Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. | 1989 | Thromb. Res. | pmid:2554526 |
| Nguyên P et al. | Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. | 1995 | Thromb. Res. | pmid:7778064 |
| Vargaftig BB et al. | Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. | 1982 | Thromb. Res. | pmid:7164036 |
| Hanss M and Dechavanne M | 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. | 1988 | Thromb. Res. | pmid:3126559 |
| Okamoto M et al. | Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. | 1986 | Thromb. Res. | pmid:3754990 |
| Sturk A et al. | Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. | 1985 | Thromb. Res. | pmid:2934863 |
| Shukla SD et al. | Hypersensitivity of diabetic human platelets to platelet activating factor. | 1992 | Thromb. Res. | pmid:1329254 |
| Kurose I et al. | Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. | 1991 | Thromb. Res. | pmid:1650966 |
| Westwick J et al. | Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. | 1986 | Thromb. Res. | pmid:3715810 |
| Valone FH | Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. | 1987 | Thromb. Res. | pmid:3590086 |
| Tokumura A et al. | Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. | 1987 | Thromb. Res. | pmid:3590110 |
| Wade PJ et al. | Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. | 1986 | Thromb. Res. | pmid:3961730 |
| Cox CP and Wood KL | Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. | 1987 | Thromb. Res. | pmid:3629553 |
| Catalán RE et al. | Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. | 1994 | Thromb. Res. | pmid:7974386 |
| Ostermann G et al. | Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. | 1987 | Thromb. Res. | pmid:3629555 |
| Heinrich J and Zimmermann RE | Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. | 1984 | Thromb. Res. | pmid:6523451 |
| Hwang SB et al. | Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. | 1984 | Thromb. Res. | pmid:6429890 |
| Petty AC and Scrutton MC | Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists? | 1989 | Thromb. Res. | pmid:2749609 |
| Lalau Keraly C et al. | Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. | 1984 | Thromb. Res. | pmid:6740569 |
| Janero DR et al. | Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. | 1988 | Thromb. Res. | pmid:3413730 |
| Moon DG et al. | Platelet activating factor and sheep platelets: a sensitive new bioassay. | 1990 | Thromb. Res. | pmid:2326773 |
| Violi F et al. | Human platelet aggregation by PAF and thromboxane production. | 1987 | Thromb. Res. | pmid:3424290 |
| Bernat A and Herbert JM | Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF. | 1994 | Thromb. Res. | pmid:8073411 |
| Klöcking HP et al. | Release of tissue-type plasminogen activator by platelet-activating factor. | 1985 | Thromb. Res. | pmid:4040278 |
| Cox CP | Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. | 1986 | Thromb. Res. | pmid:2421432 |
| Nunn B | Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. | 1983 | Thromb. Res. | pmid:6648898 |
| Croft KD and Beilin LJ | Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. | 1993 | Thromb. Res. | pmid:8385810 |
| Vrzheshch PV et al. | Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. | 1992 | Thromb. Res. | pmid:1523610 |
| Teng CM et al. | Antiplatelet actions of some coumarin compounds isolated from plant sources. | 1992 | Thromb. Res. | pmid:1523611 |
| Kohayakawa M and Inoue K | Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. | 1986 | Thromb. Res. | pmid:3083530 |
| Battistini B et al. | Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. | 1990 | Thromb. Res. | pmid:2278035 |
| Tencé M et al. | Ether-phospholipid composition in neutrophils and platelets. | 1985 | Thromb. Res. | pmid:4024039 |
| Hadváry P and Baumgartner HR | Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. | 1983 | Thromb. Res. | pmid:6868019 |
| Leoncini G et al. | Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. | 1997 | Thromb. Res. | pmid:9175236 |
| Tan EL and Snyder F | Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. | 1985 | Thromb. Res. | pmid:4024051 |
| Despotis GJ et al. | Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. | 1997 | Thromb. Res. | pmid:9175242 |
| Ding YA et al. | Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. | 1995 | Thromb. Res. | pmid:7740521 |
| Küster LJ and Frölich JC | PAF-induced platelet aggregation and TXB2 formation. | 1989 | Thromb. Res. | pmid:2922704 |
| Neiman J et al. | Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. | 1989 | Thromb. Res. | pmid:2617478 |
| Altman R et al. | Why single daily dose of aspirin may not prevent platelet aggregation. | 1988 | Thromb. Res. | pmid:3140408 |
| Lukaszyk A et al. | Does acute experimental pancreatitis affect blood platelet function? | 1989 | Thromb. Res. | pmid:2524119 |
| Lecompte T et al. | Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. | 1990 | Thromb. Res. | pmid:2117306 |
| Mabilat-Pragnon C et al. | Urokinase localization and activity in isolated eosinophils. | 1997 | Thromb. Res. | pmid:9526961 |
| Kinlough-Rathbone RL et al. | Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. | 1999 | Thromb. Res. | pmid:10527409 |
| Csáki C et al. | Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. | 1992 | Thromb. Res. | pmid:1412179 |
| May JA et al. | Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. | 1997 | Thromb. Res. | pmid:9361371 |
| Lian EC et al. | Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. | 1984 | Thromb. Res. | pmid:6420930 |